Azole derivatives as WTN pathway inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8883827
SERIAL NO

13376202

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ELUCIDERM INC7163 TORREY MESA COURT SAN DIEGO CA 92129

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Holsworth, Daniel San Diego, US 5 55
Krauss, Stefan Eidsvoll Verk, NO 27 136
Machon, Ondrej Prague, CZ 3 55
Waaler, Jo Oslo, NO 5 55

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 11, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00